Completed
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
NCT05262959
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China